Duke Signed a License Agreement with Splendo Health
Duke University and Splendo Health have entered into a license agreement. The Dutch digital health startup is a collaboration between Duke University and Splendo Consulting. Splendo Health has developed SplendoFit, a comprehensive digital platform with sensors and…
Predictive Technology Developed at Duke Promises to Reduce Inefficiencies in Surgery
“We were able to take a Duke-born technology, foster and pilot it in the entrepreneurial environment of Duke to the point it could be translated out as a start-up, partner with Duke to bring a…
Filing an Invention Disclosure Form
At Duke, an Invention Disclosure Form, or “IDF” for short, represents the first recording of an invention, and the “kick-off point” for the office to begin working with you on the best way to protect,…
TruDiagnostic Signed an Exclusive License Agreement with Duke University to use the DunedinPoAm Rate of Aging Algorithm
Lexington, KY & Durham, NC – TruDiagnostic signed the exclusive license agreement to the DunedinPoAm pace of aging methylation prediction algorithm. Pace of Aging is how quickly a person’s epigenetic markers are changing to hasten…
StrideBio Announces a Multi-technology License and Master SRA with Duke University to Advance Next-generation Gene Therapies
– StrideBio receives exclusive license to novel cross-species evolved AAV vectors and an enzymatic approach for neutralizing antibody evasion – – Master Sponsored Research Agreement will support collaborative research and development of multiple novel gene…
Campus to Commercialization: Duke’s Objectives in a License
by Robin Rasor, Executive Director, OTC OTC is the office that helps connect Duke innovations with industry, entrepreneurial management, investors, and other resources to develop the partnerships necessary to create value and benefit to society.…
Crossing the Valley of Death: Tech Transfer Marketing
By Alex Mullins, Technology Marketing Associate In the field of technology transfer, we often talk about the valley of death between academic research and the commercialization of technology. This dreaded gap occurs after a researcher…
Releviate Therapeutics Inks Exclusive License for Human Monoclonal Antibodies for Chronic Pain Indications
Therapies Based on Extensive Neuropathic Pain Research Conducted at UC Riverside and Duke University Target Chronic Pain at Its Source: Matrix Metalloproteinases October 28, 2020 09:10 AM Eastern Daylight Time SAN DIEGO–(BUSINESS WIRE)–Releviate™ Therapeutics, a…
The Indemnification Clause: What You Need to Know
By Eric Wagner, Director, Legal Affairs Indemnification. A big word that doesn’t frequently come up in everyday conversation. Unless, of course, you are a transactional attorney or a technology transfer professional. Indemnification is a…